Document is current
Any future updates will be listed below
-
Authors
Liu, Bin https://orcid.org/0000-0002-3168-8456
Dong, Xiaolong
Cheng, Haoyang https://orcid.org/0000-0003-3313-9853
Zheng, Chunwei
Chen, Zexiang https://orcid.org/0000-0002-1584-2417
Rodríguez, Tomás C. https://orcid.org/0000-0002-8724-5427
Liang, Shun-Qing
Xue, Wen https://orcid.org/0000-0002-9797-8042
Sontheimer, Erik J. https://orcid.org/0000-0002-0881-0310
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01HL131471, P01HL158506, UG3HL147367)
American Cancer Society (129056-RSG-16-093)
Cystic Fibrosis Foundation
Leducq Foundation Transatlantic Network of Excellence Program
- License Information
-
More Information
Article History
Received: 23 June 2021
Accepted: 8 February 2022
First Online: 4 April 2022
Competing interests
: E.J.S. is a co-founder and Scientific Advisory Board member of Intellia Therapeutics and a Scientific Advisory Board member at Tessera Therapeutics. The University of Massachusetts Chan Medical School has filed a patent application on this work. The authors declare no competing interests.
